Management of Diabetic Foot Ulcer with Recombinant Human Epidermal Growth Factor versus Conventional Dressing Method

Background Diabetic foot ulcer (DFU) is a serious health problem. Major amputation increases the risk of mortality in patients with DFU; therefore, treatment methods other than major amputation come to the fore for these patients. Graft applications create an appropriate environment for the reproduction of epithelial cells. Similarly, epidermal growth factor (EGF) also stimulates epithelization and increases epidermis formation. In this study, we aimed to compare patients with DFU treated with EGF and those treated with a split-thickness skin graft. Methods Patients who were treated for DFU in the general surgery clinic were included in the study. The patients were evaluated retrospectively according to their demographic characteristics, wound characteristics, duration of treatment, and treatment modalities. Results There were 26 patients in the EGF group and 21 patients in the graft group. The mean duration of treatment was 7 weeks (4-8 weeks) in the EGF group and 5.3 weeks (4-8 weeks) in the graft group (P < .05). In the EGF group, wound healing could not be achieved in one patient during the study period. In the graft group, no recovery was achieved in three patients (14.2%) in the donor site. Graft loss was detected in four patients (19%), and partial graft loss was observed in three patients (14.2%). The DFU of these patients were on the soles (85.7%). These patients have multiple comorbidities. Conclusions EGF application may be preferred to avoid graft complications in the graft area and the donor site, especially in elderly patients with multiple comorbidities and wounds on the soles.

Download Full-text

Topical epidermal growth factor (EGF) may be effective in the treatment of patients with diabetic foot ulcer,

Inpharma Weekly ◽

10.2165/00128413-200515150-00018 ◽

2005 ◽

Vol &NA; (1515) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Diabetic Foot ◽

Foot Ulcer ◽

Diabetic Foot Ulcer ◽

Epidermal Growth

Download Full-text

An Assessment of Intralesional Epidermal Growth Factor for Treating Diabetic Foot Wounds

Journal of the American Podiatric Medical Association ◽

10.7547/15-056 ◽

2017 ◽

Vol 107 (1) ◽

pp. 17-29 ◽

Cited By ~ 9

Author(s):

Bulent M. Ertugrul ◽

Benjamin A. Lipsky ◽

Ulas Guvenc ◽

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Diabetic Foot ◽

Foot Ulcer ◽

Diabetic Foot Ulcer ◽

Complete Response ◽

Major Amputation ◽

Median Frequency ◽

Surgical Interventions ◽

Epidermal Growth

Background: Intralesional epidermal growth factor (EGF) has been available as a medication in Turkey since 2012. We present the results of our experience using intralesional EGF in Turkey for patients with diabetic foot wounds. Methods: A total of 174 patients from 25 Turkish medical centers were evaluated for this retrospective study. We recorded the data on enrolled individuals on custom-designed patient follow-up forms. Patients received intralesional injections of 75 μg of EGF three times per week and were monitored daily for adverse reactions to treatment. Patients were followed up for varying periods after termination of EGF treatments. Results: Median treatment duration was 4 weeks, and median frequency of EGF administration was 12 doses. Complete response (granulation tissue >75% or wound closure) was observed in 116 patients (66.7%). Wounds closed with only EGF administration in 81 patients (46.6%) and in conjunction with various surgical interventions after EGF administration in 65 patients (37.3%). Overall, 146 of the wounds (83.9%) were closed at the end of therapy. Five patients (2.9%) required major amputation. Adverse effects were reported in 97 patients (55.7%). Conclusions: In patients with diabetic foot ulcer who received standard care, additional intralesional EGF application after infection control provided high healing rates with low amputation rates.

Download Full-text